Table 1 Clinical characteristics of patients in the discovery and validation cohort.
From: Urinary exosomal microRNA profiling in intermediate-risk prostate cancer
Variables | Discovery cohort (small RNA seq) | Validation cohort (RT-qPCR) | ||||
|---|---|---|---|---|---|---|
Non-BCR (n = 21) | BCR (n = 6) | p-value | Non-BCR (n = 28) | BCR (n = 26) | p-value | |
Mean age, years (SD) | 67.8 (5.8) | 69.3 (6.7) | 0.616 | 66.6 (6.4) | 65.2 (8.5) | 0.500 |
Pre-operative PSA (ng/mL, SD) | 7.9 (3.6) | 8.9 (4.7) | 0.670 | 7.7 (4.1) | 6.3 (2.2) | 0.101 |
Gleason score, N (%) | 0.927 | 0.061 | ||||
3 + 4 | 11 (52.4) | 3 (50) | 19 (67.9) | 11 (42.3) | ||
4 + 3 | 10 (47.6) | 3 (50) | 9 (32.1) | 15 (57.7) | ||
Pathologic stage, N (%) | ||||||
pT2a-c | 21 (100) | 6 (100) | 28 (100) | 26 (100) | ||
Margin status, N (%) | 0.056 | 0.061 | ||||
Negative | 18 (85.7) | 2 (33.3) | 21 (75) | 13 (50.0) | ||
Positive | 3 (14.3) | 4 (66.7) | 7 (25) | 13 (50.0) | ||
PIN, N (%) | 0.755 | 0.769 | ||||
Negative | 0 (0) | 0 (0) | 1 (3.6) | 0 (0.0) | ||
I | 11 (52.4) | 4 (66.7) | 9 (32.1) | 8 (30.8) | ||
II | 9 (42.9) | 2 (33.3) | 13 (46.4) | 14 (53.8) | ||
III | 1 (4.8) | 0 (0) | 5 (17.9) | 4 (15.4) | ||
Mean time to BCR, months (range) | 31.1 (9.1–52.1) | 28.5 (5.1–59.4) | ||||
